Luca Agnelli

机构：Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Tumori Foundation, Fondazione IRCCS Istituto Nazionale dei Tumori · ORCID：0000-0003-0582-6170

发表论文 373 篇 · 总被引 6067 次 · h-index 48

代表论文

• Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO (2024 · Annals of Oncology · 被引 95)
• Early downmodulation of tumor glycolysis predicts response to fasting-mimicking diet in triple-negative breast cancer patients (2024 · Cell Metabolism · 被引 29)
• The 2024 Nobel Prize in Physiology or Medicine: microRNA Takes Center Stage (2024 · Non-Coding RNA · 被引 11)
• Impact of comprehensive genomic profiling and molecular tumour board on costs and access to tailored therapies: real-world observational study (2025 · BMJ Open · 被引 10)
• Real-World Outcomes of Molecular Tumor Board Treatment Recommendations (2025 · JCO Precision Oncology · 被引 7)
• Genomic instability and CCNE1 amplification as emerging biomarkers for stratifying high-grade serous ovarian cancer (2025 · Frontiers in Oncology · 被引 6)